scholarly journals Patients with Chronic Hepatitis C - Who Should Not Be Treated?

2000 ◽  
Vol 14 (suppl b) ◽  
pp. 63B-67B
Author(s):  
Andreas Schüler ◽  
Michael Peter Manns
Keyword(s):  
Risk Factors ◽  
Hepatocellular Carcinoma ◽  
Liver Cirrhosis ◽  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Treatment Side Effects ◽  
Life Conditions ◽  
Therapy Effectiveness ◽  
Receive Treatment

The decision to treat a patient with chronic hepatitis C (CHC) is based on what is known about the risk factors for developing liver cirrhosis or hepatocellular carcinoma, as well as on conditions that contraindicate therapy or impair therapy effectiveness. Several factors, including age, treatment side effects, disease severity, concurrent diseases and life conditions, may render treatment decisions more difficult. This review focuses on identifying CHC patients who should not receive treatment.

Risk Factors of Hepatocellular Carcinoma in Chronic Hepatitis C and Cirrhosis: Special Reference to Laparoscopic Findings

1999 ◽  
Vol 11 (1) ◽  
pp. 24-31 ◽  
Author(s):  
Takao SHIBAYAMA ◽  
Shin‐iciro MORI ◽  
Hiroo OHTAKE ◽  
Seishuu HAYASHI ◽  
Shunichi SAEKI ◽  
...  
Keyword(s):  
Risk Factors ◽  
Hepatocellular Carcinoma ◽  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Special Reference ◽  
Chronic Hepatitis C

Plasma Lipidomic Fingerprinting to Distinguish among Hepatitis C-related Hepatocellular Carcinoma, Liver Cirrhosis, and Chronic Hepatitis C using MALDI-TOF Mass Spectrometry: a Pilot Study

2015 ◽  
Vol 24 (1) ◽  
pp. 43-49 ◽  
Author(s):  
Ana Maria Passos-Castilho ◽  
Edson Lo Turco ◽  
Maria Lúcia Ferraz ◽  
Carla Matos ◽  
Ivonete Silva ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
Hepatocellular Carcinoma ◽  
Liver Cirrhosis ◽  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Predictive Accuracy ◽  
Maldi Ms ◽  
Charge Ratio ◽  
Ionization Mass

Background & Aims: Hepatitis C (HC) is a major cause of hepatocellular carcinoma (HCC), and a late diagnosis is the main factor for the poor survival of patients. There is an urgent need for identifying sensitive and specific biomarkers for HCC diagnosis. In the present study, plasma lipid patterns of patients with HC-HCC, HC-liver cirrhosis (LC), and chronic HC (CHC) were assessed by matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS).Methods. Plasma samples of 25 patients with HC-HCC, 15 patients with HC-LC, and 25 patients with CHC were evaluated by MALDI-MS using a Q-ToF premier (Synapt) mass spectrometer (Waters, Manchester, UK) equipped with a 200-Hz solid-state laser in the mass range between m/z (mass-to-charge ratio) of 700-1200.Results. A total of 2205 ions were initially obtained and 7 ions (m/z) were highlighted as corresponding to the most important lipids to differentiate HCC patients from LC and CHC patients. The specific lipidomic expression signature generated resulted in an overall predictive accuracy of 93% of HC-HCC and HC-LC, and 100% of HC-HCC and CHC. The 7-peak algorithm distinguished HCC from LC with a sensitivity of 96% and a specificity of 87%, and HCC from CHC with both sensitivity and specificity of 100%.Conclusion. MALDI-MS-specific signature peaks accurately distinguished patients with HC-HCC from those with HC-LC and CHC. The results indicate the potential of MALDI-MS and the selected peaks to improve HCC surveillance in patients with viral C cirrhosis and chronic hepatitis C.

scholarly journals Hepatocellular carcinoma in patients with chronic hepatitis C: Experience gained at Clinical Center of Vojvodina

2014 ◽  
Vol 67 (suppl. 2) ◽  
pp. 31-38
Author(s):  
Maja Ruzic ◽  
Milotka Fabri ◽  
Tomislav Preveden ◽  
Sanja Stojanovic ◽  
Zoran Milosevic ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cirrhosis ◽  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Virus Infection ◽  
Chronic Hepatitis C ◽  
Alpha Fetoprotein ◽  
Focal Lesion ◽  
Hepatitis C Virus Infection

Introduction. The incidence of chronic hepatitis C and its consequences, liver cirrhosis and hepatocellular carcinoma is growing rapidly. The aim of this study was to evaluate clinical characteristics of patients with hepatocellular carcinoma and chronic hepatitis C treated at the Clinical Centre of Vojvodina and therapy options. Material and Methods. This retrospective study included 51 patients (52.9% male and 47.1% female) with chronic hepatitis C and hepatocellular carcinoma treated between 2000 and 2014. The average age of patients was 61.6 years (SD=10.8) and the average duration of hepatitis C virus infection was 30.2 years (SD=11.7). All patients had liver cirrhosis and 43.1% had previously been treated with pegylated interferon and ribavirin. According to the Barcelona Clinic Liver Cancer criteria, stadium A, B, C and D were found in 15.7%, 52.3%, 19.6% and 11.8% of the patients, respectively. The average value of alpha fetoprotein at the moment of making diagnosis of hepatocellular carcinoma was 397.56 ng/ml and the level of alpha fetoprotein was below 20mg/ml in 26% of patients. Tumor resection, radiofrequency ablation, chemoembolization, systemic chemotherapy and liver transplantation were performed in 13.7%, 3.9%, 1.9%, 1.9% and 5.9% of patients, respectively. Average survival time after the diagnosis of hepatocellular carcinoma among patients included in the study was 1.39 (SD=1.61) years. Conclusion. Ultrasound examinations of the patients with liver cirrhosis caused by hepatitis C virus infection are obligatory every 3 months. Etiology of every focal lesion in the liver must be clarified, which could increase the possibility of administration of available therapeutic methods.

scholarly journals Risk Factors for Hepatocellular Carcinoma

2018 ◽  
Vol 15 (6) ◽  
pp. 7-20
Author(s):  
Marilena Stoian ◽  
Victor Stoica
Keyword(s):  
Risk Factors ◽  
Hepatocellular Carcinoma ◽  
Liver Cirrhosis ◽  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Liver Cancer ◽  
Hepatitis B ◽  
Rate Ratio ◽  
Obesity And Diabetes ◽  
Rate Ratios

AbstractHepatocellular carcinoma (HCC), the third leading cause of cancer deaths worldwide, with incidence rising is expected to increase by another 81% by the year 2020, primarily due to the hepatitis C epidemic. The strongest risk factors for the development of HCC is a hepatitis B (HBV) and hepatitis C (HCV) virus infection, as well as cirrhosis of any cause. Other risk factors that have been reported include exposure to aflatoxin, alcohol, tobacco, obesity and diabetes. To detect potentially curable cases of hepatocellular carcinoma, outpatients with chronic liver disease who have been seen at the Dr. Ion Cantacuzino Hospital, since 10 years and examined periodically with real-time ultrasonography and measurement of serum alpha-fetoprotein.We analyzed the data on these patients for risk factors for hepatocellular carcinoma.The risk of liver cancer in men was 1.33 times higher than in women; patients in their 60s had significantly higher rate ratios (6.46) than patients in their 40s; patients with liver cirrhosis diagnosed at enrollment had significantly higher rate ratios for liver cancer (1.93) than patients with chronic hepatitis. The high serum alpha-fetoprotein level at enrollment was also confirmed as a significant marker for a high risk, regardless of the stage of disease (chronic hepatitis or liver cirrhosis). The serum markers for hepatitis virus -- HBsAg, and anti-HCV - were significantly associated with the risk of liver cancer: the adjusted rate ratios for HBsAg, anti-HBc, and anti-HCV were estimated to be 6.92, 4.54, and 4.09, respectively. Hepatitis B surface antigen (rate ratio 6,92; 95% CI: 2.92 to 16.39) and hepatitis C antibody (rate ratio 4.09; 95% CI: 1.30 to 12.85) showed the most risk for carcinoma.Further studies are required to clarify the roles of other risk factors, including drinking and smoking habits.

Sign in / Sign up

Export Citation Format

Share Document